UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 23, 2007
Medicis Pharmaceutical Corporation
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation)
|
|
0-18443
(Commission
File Number)
|
|
52-1574808
(IRS Employer
Identification No.) |
8125 North Hayden Road
Scottsdale, Arizona 85258-2463
(Address of principal executive offices) (Zip code)
(602) 808-8800
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 1.01 Entry into a Material Definitive Agreement
On August 23, 2007, Ucyclyd Pharma, Inc. (“Ucyclyd”), a Maryland corporation and
wholly-owned subsidiary of Medicis Pharmaceutical Corporation, a Delaware corporation (the
“Company”), and Hyperion Therapeutics, Inc., a Delaware corporation (“Hyperion”),
executed a Collaboration Agreement (the “Agreement”), pursuant to which Hyperion will
continue the ongoing research and development of Ucyclyd’s product referred to as “GT4P” for the
treatment of Urea Cycle Disorder (“UCD”), Hepatic Encephalopathies (“HE”) and other
indications, and additional indications for AMMONUL® (collectively, the “Research
Projects”). In addition, Hyperion will co-promote Ucyclyd’s existing on-market products
AMMONUL® and BUPHENYL® (the “Existing On-Market Products”) for the
treatment of UCD. In exchange for the rights and licenses granted to Hyperion under the Agreement,
Hyperion will pay Ucyclyd a fee of $10 million. Moreover, if certain conditions are satisfied
relating to the Research Projects, Hyperion will be entitled to certain buyout rights to Ucyclyd’s
development products and Existing On-Market Products, and will pay Ucyclyd royalties and regulatory
and sales milestone payments in connection with certain licenses that would be granted to Hyperion
upon exercise of such buyout rights with respect to “GT4P” for various indications and
AMMONUL® for HE.
On August 28, 2007, the Company and Hyperion issued a joint press release announcing the
strategic collaboration between Hyperion and Ucyclyd. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
| |
|
|
| Exhibit |
|
Description |
|
|
|
99.1
|
|
Joint press release, dated August 28, 2007, announcing the strategic collaboration between
Hyperion and Ucyclyd. |